HHS Delays Multiple Best Price Reporting Rule
- November 19, 2021
The Department of Health and Human Services is delaying by six-months provisions of a final rule (85 Fed Reg. 87000) that allowed drug manufacturers to report multiple best prices to Medicaid if the prices are tied to a value-based arrangement.
You must be logged in to access this content.